Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation
Inflammation Immunology Drug Pipeline & Clinical Trials
Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.
On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.
If you are a Health Care Professional and interested in further details (including pathways being explored, mechanisms of action of investigational compounds, and an overall summary of investigational compounds organized by therapy area and disease state), please visit our in-depth Pfizer Immunology & Inflammation Research Pipeline site.
PF-07314470 | New project
Atopic Dermatitis (Biologic)
undisclosed
CTB+AVP (PF-07612577) | New project
Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis
Beta lactam/Beta lactamase inhibitor
PF-07985631 | Project advanced
Nephropathy (Biologic)
undisclosed
PF-07832837 | New project
Atopic Dermatitis (Biologic)
undisclosed
PF-08049820 | New project
Atopic Dermatitis
undisclosed
PF-07940369 | New project
Anemia of Clonal Hematopoiesis (ACH)
undisclosed
PF-07905428 | New project
Acne
undisclosed
PF-06414300 | New project
Ulcerative Colitis
undisclosed
PF-07899895 | New project
Ulcerative Colitis
SIK inhibitor
PF-07054894 | New project
Ulcerative Colitis
CCR6 antagonist
PF-06835375 | New project
Lupus (Biologic)
anti-CXCR5
Dekavil | New project
Rheumatoid Arthritis (Biologic)
IL-10
PF-072612712 | Project advanced
Inflammatory Bowel Disease (Biologic)
p40/TL1a bispecific
PF-07868489 | New project
Pulmonary Arterial Hypertension (Biologic) (ORPHAN - U.S.)
anti-BMP9
PF-07264660 | New project
Atopic Dermatitis (Biologic)
anti-IL-4/ IL-13/ IL-33
PF-07275315 | New project
Asthma (Biologic)
anti-IL-4/ IL-13/ TSLP
PF-07275315 | New project
Atopic Dermatitis (Biologic)
anti-IL-4/ IL-13/ TSLP
PF-06835375 | New project
Immune Thrombocytopenic Purpura (Biologic)
anti-CXCR5
dazukibart (PF-06823859) | New project
Lupus (Biologic)
anti-IFN-B
LITFULO (ritlecitinib) | New project
Crohn's Disease
JAK3/TECinhibitor
LITFULO (ritlecitinib) | New project
Ulcerative Colitis
JAK3/TECinhibitor
inclacumab (PF-07940370) | New project
Vaso-occlusive (VOC) reduction in patients with Sickle Cell Disease (Biologic)
Anti-P-selectin
osivelotor (PF-07940367) | New project
Sickle Cell Disease (RPD, FAST TRACK, ORPHAN - U.S.)
HbS polymerization inhibitor
HYMPAVZI (marstacimab) | New project
Hemophilia (inhibitor cohort) (Biologic) (FAST TRACK, ORPHAN - U.S.)
Anti-tissue factor pathway inhibitor
HYMPAVZI (marstacimab) | New project
Hemophilia (Pediatric: inhibitor and non-inhibitor cohorts) (Biologic) (ORPHAN - U.S.)
Anti-tissue factor pathway inhibitor
dazukibart (PF-06823859) | New project
Dermatomyositis, Polymyositis (Biologic) (ORPHAN - U.S. E.U., FAST TRACK - U.S., PRIME - E.U.)
anti-IFN-B
LITFULO (ritlecitinib) | New project
Vitiligo
JAK3/TEC inhibitor